Nephropathy and Retinopathy screening in 88 Type 2 Diabetics: a Real-World 3 Year Experience

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: MON 776-795-Cardiometabolic Risk & Vascular Biology
Clinical
Monday, June 17, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board MON-795
Tiago Lopes Nunes da Silva*, Henrique Vara Luiz, Bernardo Dias Pereira, Andreia Veloza, Ana Catarina Matos, Isabel Manita, Maria Carlos Cordeiro, Luísa Raimundo and Jorge Portugal
Garcia de Orta Hospital, Almada, Portugal
Diabetic Nephropathy (DN) and Diabetic Retinopathy (DR) usually have a long sub-clinical phase, in which intervention can delay its progression.

The authors studied the prevalence and progression of ND and RD in type 2 diabetes (DM2) patients, who attended an Endocrinology Center.

Both DN and DR were studied retrospectively in 88 DM2 patients during 3 years of follow-up in a Hospital based Endocrinology Center (2006 through 2009). DN was evaluated using MDR to predict glomerular filtration rate (GFR) and by the presence of albuminuria in 24 hour urine sample. DR was studied using the records from ophthalmology clinics. Normally distributed variables were displayed as means and standard deviations. Where appropriate, one-way ANOVA or paired t-test were used.

At baseline, the average GFR was 93 ml/min; 19% had micro-albuminuria and 10% had macro-albuminuria and a mean of 65% of the patients were treated with angiotensin receptor antagonists (ARA) or angiotensin converter enzyme inhibitors (ACEI)

At the end of the 3 years, the average GFR was 101 ml/min (NS); 22% had micro-albuminuria (NS) and 16% had macro-albuminuria (NS) and there was an increase to 76% in the number of the patients treated with ARA or ACEI (NS).

At baseline, 50% of patients had been screened for DR; 27% had non proliferative DR and 30% had proliferative DR. At the end of the 3 years, only 47% of patients had at least been screened once for DR; 27% had non proliferative DR and 37% had proliferative DR.

At the end of the 3 years of study, DN did not progress. At the same time there was a significant increase in the prescription of ARA/ACEI. There was a suboptimal screening for DR in this real-world study.

Nothing to Disclose: TLN, HVL, BDP, AV, ACM, IM, MCC, LR, JP

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm

<< Previous Abstract | Next Abstract